title: Photodynamic therapy of idiopathic and inflammatory choroidal neovascularization in young adults.
abstract: OBJECTIVE
  To evaluate the treatment of subfoveal choroidal neovascularization (CNV) using photodynamic therapy (PDT) with verteporfin (Visudyne; Novartis, Duluth, GA) in young adults.
  
  
  METHODS
  Retrospective noncomparative interventional case series.
  
  
  METHODS
  Nineteen eyes of 17 patients with classic, subfoveal CNV treated with PDT using verteporfin, excluding eyes with CNV secondary to age-related macular degeneration, angioid streaks, and myopia.
  
  
  METHODS
  Snellen visual acuity before and after PDT.
  
  
  RESULTS
  Nineteen eyes were followed an average of 12.8 months (range, 4-33 months) after PDT. Before treatment, visual acuity measured > or = 20/40 in 0 eyes (0.0%), < 20/40 to > 20/200 in 11 eyes (57.9%), and < or =20/200 in 8 eyes (42.1%). After treatment, visual acuity measured > or =20/40 in four eyes (21.1%), < 20/40 to > 20/200 in eight eyes (42.1%), and < or =20/200 in seven eyes (36.8%). Six eyes (31.6%) underwent retreatment, with only two eyes retreated twice. Four eyes underwent eventual surgical removal of the CNV after PDT.
  
  
  CONCLUSIONS
  Photodynamic therapy seems to be useful in stabilizing and improving visual acuity in young adults with subfoveal CNV secondary to idiopathic and inflammatory etiologies.
authors.affiliation: New England Eye Center, Tufts University School of Medicine, 750 Washington Street, Boston, MA 02111, USA.
authors.forename: Adam H
authors.initials: AH
authors.lastname: Rogers
authors.forename: Jay S
authors.initials: JS
authors.lastname: Duker
authors.forename: Neil
authors.initials: N
authors.lastname: Nichols
authors.forename: Brad J
authors.initials: BJ
authors.lastname: Baker
mesh_terms: D000328:Adult; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D002833:Choroiditis / Q000150:complications / Q000188:drug therapy*; D005260:Female; D005451:Fluorescein Angiography; D005584:Fovea Centralis; D006801:Humans; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011166:Porphyrins / Q000627:therapeutic use*; D012189:Retrospective Studies; D016896:Treatment Outcome; D000077362:Verteporfin; D014792:Visual Acuity
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin